CSBTF (Kuros Biosciences) Selling, General, & Admin. Expense: $101.5 Mil (TTM As of Dec. 2025)


CSBTF Kuros Biosciences Ltd CSBTF
71 GF Score
Price $24.07
GF Value $54.53
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Kuros Biosciences Selling, General, & Admin. Expense?

Kuros Biosciences CSBTF +5.94% 71 Selling, General, & Admin. Expense is $101.5 Mil as of Dec. 2025. GuruFocus rates CSBTF with a GF Score™ of 71/100 and a GF Value™ of $54.53 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Kuros Biosciences's selling, general, & admin. expense for the six months ended in Dec. 2025 was $53.8 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2025 was $101.5 Mil.


Kuros Biosciences  (OTCPK:CSBTF) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Kuros Biosciences Selling, General, & Admin. Expense Related Terms


Kuros Biosciences Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for Kuros Biosciences's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kuros Biosciences Selling, General, & Admin. Expense Chart

Kuros Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.01 11.97 23.92 52.16 102.43

Kuros Biosciences Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.79 28.71 23.37 47.65 53.81

CSBTF vs ABT, SYK, MDT: Selling, General, & Admin. Expense Comparison

For the Medical Devices subindustry, Kuros Biosciences's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kuros Biosciences Selling, General, & Admin. Expense vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Kuros Biosciences's Selling, General, & Admin. Expense falls into.


CSBTF
71GF Score
Kuros Biosciences Ltd CSBTF
Selling, General, & Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kuros Biosciences Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $101.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of $101.5 Mil mean?
Kuros Biosciences (CSBTF) has a Selling, General, & Admin. Expense of $101.5 Mil as of Dec. 2025. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Kuros Biosciences and its competitors.
Is Kuros Biosciences' Selling, General, & Admin. Expense too high?
Kuros Biosciences' current Selling, General, & Admin. Expense is $101.5 Mil. Overall, Kuros Biosciences has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' Selling, General, & Admin. Expense compare to ABT and SYK?
Kuros Biosciences' Selling, General, & Admin. Expense of $101.5 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Medical Devices & Instruments company?
A good Selling, General, & Admin. Expense depends on the Medical Devices & Instruments industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Kuros Biosciences and its competitors. Kuros Biosciences's current Selling, General, & Admin. Expense is $101.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (CSBTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $54.53, compared to a current price of $24.07 — trading 55.9% below its estimated fair value. The current Selling, General, & Admin. Expense is $101.5 Mil. Kuros Biosciences' overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Kuros Biosciences (CSBTF), the current Selling, General, & Admin. Expense is $101.5 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kuros Biosciences (CSBTF) Overvalued in 2026?

Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued. The current stock price of $24.07 is trading 55.9% below its estimated GF Value™ of $54.53. GuruFocus considers Kuros Biosciences to be Significantly Undervalued.

Key valuation signals for CSBTF:

  • Selling, General, & Admin. Expense: $101.5 Mil
  • GF Value™: $54.53 vs. price of $24.07 (55.9% below fair value)
  • GF Score™: 71/100 with 2 warning signs

No single metric tells the full story. See the CSBTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kuros Biosciences Business Description

Address Wagistrasse 25, Schlieren, Zurich, CHE, 8952
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
71GF Score

Get the complete analysis for CSBTF

Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.07
Price
$54.53
GF Value